Tagged with IT

Switzerland While Switzerland has Europe’s second-highest proportion of women in the workforce, it trails global standards on gender diversity in boardrooms and in management positions. However, this situation is changing and two of Switzerland’s most important pharma affiliates are at the forefront of a new wave of diverse Swiss leadership teams.…

USA Dr Philipp Diesinger and Dr Gabriell Máté outline why a data-driven approach can help optimise patient copay assistance programs in the US across a wide range of patient groups, increasing access and driving down costs in the process.   2020 has been an exceptionally turbulent year – especially for the…

Switzerland Pfizer Switzerland’s Sabine Bruckner discusses Switzerland’s historic and continuing importance to Pfizer, vaccine development and uptake, and the significant benefits of building a diverse leadership team.   There are challenges and opportunities in every situation and, while there is no doubt that COVID-19 is challenging for all of us, it…

Switzerland Alfasigma Switzerland’s Dr Tytus Litynski introduces the Italian firm’s diversified portfolio of both Rx drugs and food supplements in Switzerland, why internal innovation remains the company’s core focus, and how stakeholder relations have had to evolve in the COVID-19 era.   One advantage of being a family-owned rather than a…

Norway BMS Norway’s Hilde Bech outlines her hopes of bringing “the medicines of the future” to Norwegian patients, why tiny Norway still has global significance for the company, and offers some pearls of wisdom for the next generation of female leaders.   BMS Norway is absolutely going to be one of…

Switzerland Intergenerika’s Dr Axel B. Müller makes an impassioned case against the introduction of a reference pricing system in Switzerland, arguing that it would hurt not only the Swiss generics industry but, ultimately, patients. Dr Müller proposes an alternative way, leveraging the pre-existing system to generate healthcare savings, outlines the dynamics…

Switzerland Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why Switzerland will continue to play a vital role in Biogen’s global clinical research footprint, and some of the country’s market access and pricing challenges. Dr Gasser also highlights Biogen’s burgeoning…

Switzerland Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey, Janssen’s commitment to bringing transformational medical innovations to Swiss patients, as well as his perspectives on talent development within the industry.   Switzerland is very open to innovative products, and…

Switzerland The USA is now Switzerland’s biggest export market and in 2019 Switzerland exported more to the US than to France, Italy, the UK and Austria combined and twice as much as Brazil, Russia, India and China combined. However, as Martin Naville of the American Chamber of Commerce in Switzerland recently…

UK The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as its third largest export destination. However, with the Japanese government having previously expressed concern about uncertainties arising from the Brexit…

Switzerland Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to face significant delays and roadblocks in their introduction to the domestic Swiss market. Key stakeholders from pharma industry associations Interpharma and scienceindustries and local affiliate heads for multinationals Bayer…

Switzerland scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how the country’s evolving relationship with the EU stands to impact the industry, and Switzerland’s progress on the road to full digitalisation and Pharma 2.0   What our members want is a good and stable…